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Native electrospray mass 
spectrometry approaches to probe 
the interaction between zinc and 
an anti-angiogenic peptide from 
histidine-rich glycoprotein
Esther M. Martin1,2, Frances D. L. Kondrat3,4, Alan J. Stewart  5, James H. Scrivens3,6,  
Peter J. Sadler  1 & Claudia A. Blindauer1
Zinc modulates the biological function of histidine-rich glycoprotein (HRG) through binding to its His-
rich region (HRR). The Zn2+-binding properties of a 35 amino-acid biologically-active peptide mimic of 
the HRR, HRGP330, were investigated using dissociative mass spectrometry approaches in addition 
to travelling-wave ion mobility mass spectrometry (TWIM-MS). Native mass spectrometry confirmed 
zinc binding to HRGP330; however, broadening of the 1H NMR resonances upon addition of Zn2+ ions 
precluded the attainment of structural information. A complementary approach employing TWIM-MS 
indicated that HRGP330 has a more compact structure in the presence of Zn2+ ions. Top-down MS/MS 
data supported a metal-binding-induced conformational change, as fewer fragments were observed for 
Zn2+-bound HRGP330. Zn2+-bound fragments of both N-terminal and C-terminal ends of the peptide 
were identified from collision-induced dissociation (CID) and electron transfer dissociation/proton 
transfer reaction (ETD/PTR) experiments, suggesting that multiple binding sites exist within this region 
of HRG. The combination of mass spectrometry and NMR approaches provides new insight into the 
highly dynamic interaction between zinc and this His-rich peptide.
Histidine-rich peptides, loops and regions are ubiquitous in the proteomes of all organisms1,2. They are found 
in antimicrobial histatins3, snake venoms4, proteins involved in metal ion homeostasis5, and proteins mediating 
interactions with anionic molecules or surfaces6. There are no resolved 3D structures available for any His-rich 
region; invariably such regions have proven to be refractory to classical structural analysis, most likely due to 
structural disorder7. Indeed, His-rich proteins and peptides are one prominent example of intrinsically disor-
dered proteins6.
An important property of His-rich proteins and peptides is their ability to bind metal ions, and in many cases, 
this ability relates to their biological function. In organisms, they are predominantly associated with Ni2+, Cu2+, 
and Zn2+ 1. One particularly intriguing example is the His-rich region (HRR) from mammalian histidine-rich gly-
coproteins (HRGs). Human HRG is a 75 kDa plasma protein8 that was first isolated from human serum in 19729. 
It is synthesised in the liver and is present in plasma at a relatively high concentration (ca. 1.5–2 µM). HRG pos-
sesses a multi-domain structure, consisting of six functional domains (Fig. 1A)10,11. These include two N-terminal 
regions, N1 and N2, which display homology to cystatins. The X-ray crystal structure of the N2 domain was 
recently reported, confirming that it exhibits a cystatin-like fold12. The HRR (Fig. 1B) contains repeating units 
of GHHPH pentapeptides, and is flanked at either side by Pro-rich regions (PRR). Finally, there is a C-terminal 
domain. Four intradomain and two interdomain disulfide bonds as well as six predicted N-glycosylation sites at 
various Asn residues are distributed across the protein1,13.
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HRG is able to interact with many ligands14,15 including proteins such as plasminogen16, fibrinogen17, 
thrombospondin-1 (TSP-1)18, vasculostatin19, and immunoglobulins20. Other binding partners include hepa-
rins and heparan sulfate21, heme22,23, and metal cations such as Cu2+ and Zn2+ 24. In this context, the HRR is a 
particularly interesting part of the protein, as not only are the imidazole nitrogens of this region thought to play 
a major role in Zn2+ binding, but the latter has also been shown to enhance many of the reported HRG-ligand 
interactions, at physiologically relevant concentrations25–30.
HRG is involved in the regulation of numerous biological processes including coagulation, immune com-
plex clearance and angiogenesis, processes which have to be tightly controlled. Unregulated angiogenesis, the 
process by which new blood vessels are formed after injury, is associated with pathological conditions including 
ischemia, rheumatoid arthritis and cancer31. Indeed, the design and use of molecules that inhibit angiogenesis 
constitutes an important therapeutic strategy in cancer treatment. It has been proposed that the HRR region of 
HRG may be proteolytically released from HRG by plasmin (as shown in Fig. 1A) to give rise to a fragment with 
anti-angiogenic properties32. Our recent identification of an in vivo S-glutathionyl adduct at Cys185 of the N2 
domain of rabbit HRG supports this hypothesis12. Cys185 usually forms a bridged disulfide bond with a cysteine 
residue in this region (Cys407 in rabbit HRG) that must be cleaved to allow plasmin-mediated release of the 
HRR-containing fragment from the intact protein.
Significantly, even shorter segments of the HRR have shown anti-angiogenic activity33. HRGP330 is a 35 
amino acid peptide derived from the HRR of human HRG (Fig. 1B). Its primary sequence consists of amino 
acids 330–364. HRGP330 at a concentration of 100 ng/mL was able to inhibit chemotaxis of primary endothelial 
cells following stimulation by vascular endothelial growth factor. It is thought that the interaction of this and 
other HRG-derived peptides is mediated by binding to cell surface heparan sulfate34. Importantly, these inter-
actions are enhanced by the presence of Zn2+. Likewise, the broad-spectrum antimicrobial activities of HRG 
and HRG-derived His-rich peptides are also Zn2+ dependent13. These findings suggest that peptides which cor-
respond to particular sections of the HRR mimic some of the molecular properties associated with HRG or its 
large proteolytic fragment. Moreover, given that the peptides themselves exhibit Zn2+-dependent anti-angiogenic 
activity and have potential therapeutic value, their interaction with Zn2+ ions is of immediate interest. We there-
fore initiated studies on Zn2+ complexes of HRGP330.
Questions that we sought to address include (i) how many zinc ions can be bound by the peptide? (ii) does 
zinc binding have an impact on structure? and (iii) is it possible to identify individual zinc binding sites? In the 
present study, we will show how native electrospray mass spectrometry (nESI-MS), travelling wave ion mobility 
mass spectrometry (TWIM-MS), and top-down mass spectrometry, in combination with 1H NMR spectroscopy, 
substantially contribute towards answering all three questions.
Results
Native mass spectrometry identifies multiple Zn-bound species. nESI-MS allows study of intact 
biomolecules in states that are typically close to the native fold35–37. In contrast to standard mass spectrometry 
Figure 1. Domain structure and HRR sequences of HRG. (A) Domain structure of human HRG showing 
the disulfide bridging arrangement and six putative glycosylation sites. The disulfide bridge between the N2 
domain and the fragment which can be released by plasmin-mediated cleavage is highlighted in red. Notably, 
this fragment contains the entire HRR. (B) Sequence alignment of the HRR of HRG from various mammalian 
species. The sequence of the 35-residue HRGP330 peptide is highlighted in yellow. Amino acids are coloured 
according to their chemical properties: hydrophobic (black), acidic (red), basic (blue), hydrophilic (green). 
Symbols represent conservation of amino acids: fully conserved (*), conservation between groups with strongly 
similar properties (:) and conservation between groups of less similar properties (.). The sequence for rabbit 
HRG, which has been recently amended11, corresponds to NCBI reference sequence XP_008264798.1.
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conditions, this involves working with aqueous solutions at around neutral pH, with little or no organic solvent 
added. Crucially, this allows preservation of the protein tertiary structure as well as non-covalent interactions, 
and thus protein-ligand complexes can be investigated38. This includes interactions with essential metal ions such 
as Zn2+ 39–44. nESI-MS is the only method providing direct and simultaneous information on stoichiometry and 
speciation of metal-protein complexes present in a mixture, having the unique ability to report on each individual 
species present45–47.
Crude synthetic HRGP330 was purified by Reverse-Phase-HPLC (Supplementary Fig. S1) and its identity 
was confirmed by ESI-MS. An experimental average neutral mass of 4333.98 Da was determined, within 1 Da 
of the theoretical average neutral mass of 4334.58 Da (Supplementary Fig. S2). HRGP330 was incubated at var-
ying Zn/peptide molar ratios and then analysed by nESI-MS. Figure 2 shows the resulting deconvoluted mass 
spectra. These indicate that several different HRGP330-metal species are formed. At a HRGP330:Zn2+ ratio 
of 1:1, Zn1-HRGP330 was observed at the same intensity as the peak for apo-HRGP330. A small amount of 
Zn2-HRGP330 was also present at this stage. The latter form was the most abundant at 2 molar equivalents (mol. 
eqs.) of Zn2+, and the apo-form had almost completely disappeared. When 5 mol. eqs. of Zn2+ were present in the 
reaction mixture, a range of HRGP330-Zn species were observed. The Zn4 form was the most abundant, followed 
by Zn5 and Zn3, whilst the Zn6 and Zn2 forms were also identifiable in very low amounts. In its 35-aa sequence, 
HRGP330 contains 17 His and 4 Glu or Asp residues, i.e. up to 21 residues with appreciable potential for metal 
binding. Assuming a requirement for at least four ligands per Zn2+ and only mono-dentate binding would thus 
allow for up to 5 Zn2+ ions to be bound. The occurrence of the Zn6 form at the 5:1 ratio suggests that the maximal 
binding capacity of the peptide may involve either further residues (e.g. glutamines), the possibility of aspartates 
and glutamates acting as bridging ligands, or the population of binding sites with less than four peptide-derived 
ligands.
Zinc binding severely broadens 1H NMR signals of HRGP330. 1H NMR spectroscopy was used to 
study qualitatively the effects of zinc binding on structure and dynamics of HRGP330. The 1D and 2D 1H NMR 
spectra of apo-HRGP330 (Figs 3 and S3) were relatively well-resolved, but showed limited dispersion of reso-
nances. The closeness of observed 1H chemical shifts of backbone protons to so-called random-coil shifts indi-
cates that no regular secondary or tertiary structure is adopted. This is consistent with the idea that HRGP330 is 
an example of an intrinsically disordered peptide, which is also supported by the appearance of its far-UV CD 
spectrum (Supplementary Fig. S4). From their aromatic cross-peaks, at least 11 His residues were distinguishable, 
but only very limited sequential assignment was possible due to the lack of dispersion.
Upon addition of 1 mol. eq. of ZnCl2 both aromatic side-chain (from His) and backbone NH resonances 
showed considerable line broadening (Fig. 3). No new peaks were observed across the spectrum upon addition 
of Zn2+. Inspection of 2D TOCSY NMR data for this sample (Supplementary Fig. S5) revealed that all imidazole 
cross-peaks were already broadened beyond detection at this molar ratio, whilst the side-chain amide proton 
signals of Gln residues, as well as the proton signals of most aliphatic side-chains, were still readily detectable. The 
fact that all His side-chains were equally affected may suggest that there is no clearly defined preferential binding 
site. In addition, all previously observed backbone amide resonances, with the exception of Asp1 and Leu2, had 
broadened beyond detection, a typical sign of configurational and/or conformational fluctuations on an inter-
mediate timescale. After addition of 2 mol. eq. ZnCl2, even more severe line-broadening was observed, and when 
higher metal:peptide ratios were used, the overall signal-to-noise ratio decreased markedly, indicative of a loss 
of peptide in solution. Indeed, at these higher concentrations of Zn2+, extensive aggregation of the peptide was 
visible as a precipitate in the NMR tube. This is likely a consequence of the relatively high concentrations used 
in the NMR experiment, as only a small amount of dimer (~1.5 % relative intensity, not shown) and no higher 
oligomers were observed in samples analysed by ESI-MS. It may be assumed that the oligomers and aggregates 
involve inter-peptide Zn bridges.
Figure 2. Deconvoluted ESI-MS spectra of HRGP330 incubated at varying Zn2+:peptide ratios. Peptide 
samples (15 μM) in 10 mM ammonium acetate (pH 7.40) were titrated with zinc acetate and were analysed on a 
maXis QToF mass spectrometer (Bruker Daltonics). The isotopic distribution for the 1:1 Zn-HRGP330 complex 
is shown on the right hand side together with a comparison to the theoretical model.
www.nature.com/scientificreports/
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Therefore, due to generally low spectral dispersion, coupled with significant line broadening even at the lowest 
Zn2+ ratio, and oligomerisation and precipitation at higher Zn2+ concentrations, no further structural infor-
mation on the HRGP330-Zn complexes could be gleaned from the NMR experiments. The behaviour in NMR 
experiments exhibited by HRGP330 upon zinc addition is quite typical for metal-binding peptides interacting 
with Zn2+ 48. The disappearance of backbone NH resonances from a relatively small peptide can be caused by 
several processes, including oligomerisation and intermediate exchange between multiple species. Based on the 
loss of signals at higher Zn2+ ratios as well as on the ESI-MS data shown in Fig. 2, it can be suggested that in the 
present case, both processes may be involved in causing this observation. We therefore employed TWIM-MS 
to obtain global structural information on several individual zinc-bound HRGP330 species, under conditions 
disfavouring oligomerisation and aggregation.
Conformational diversity of HRGP330 increases upon zinc binding. nESI-MS becomes an even 
more powerful technique when combined with Ion-Mobility-MS (IM-MS)35. Here, the addition of a gas-filled 
mobility cell allows separation of ions by their size, as more compact ions travel through the gas at higher veloc-
ity49. IM-MS can provide insight into the overall shape of the molecules studied, with more compact conform-
ers interacting less with the mobility gas than more extended/unfolded conformers. In the case of proteins and 
peptides, this relates to folding, with more compact conformers travelling faster than more extended/unfolded 
conformers. IM-MS has been applied successfully to metalloproteins43,44,50–57, and has been shown to give infor-
mation on protein conformation that is complementary to other more traditional techniques. IM-MS is particu-
larly useful in cases where the molecules under study are not amenable to classical structural analysis58,59, such as 
encountered in the present case.
Therefore, TWIM-MS (Travelling-wave ion mobility mass spectrometry) was used to examine how Zn2+ 
affects the conformation of the HRGP330 peptide. A comparison of the arrival-time distributions (ATD) for the 
5+ charge state of apo-HRGP330 and the various Zn2+-peptide complexes is shown in Fig. 4.
Apo-HRGP330 produced a narrow peak distribution, whilst all four zinc-bound species (detected in a single 
sample) showed much broader ATDs. Since ATDs are correlated to collisional cross-sections, a broader ATD is 
usually interpreted as an indication for the presence of a wider range of conformers; in the present case, it is likely 
that configurational isomers, with Zn2+ ions bound in different locations, also contribute to this observation. 
It is also significant that the average arrival time decreased upon zinc binding, indicating that the zinc-bound 
conformers were on average more compact than the apo-form. This is a commonly observed behaviour, even for 
non-specific complexes of metal ions with small peptides60. Thus, although the observed compaction in the gas 
phase is consistent with the idea that zinc binding restricts the flexibility of the peptide, it is insufficient evidence 
to postulate a specific zinc-induced conformational change.
Zinc binds to multiple sites in Zn1-HRGP330. Considering that under basal physiological conditions, 
HRG in blood plasma, and by inference HRGP330, is expected to have not more than one molar equivalent of 
Zn2+ bound30, it was of interest to investigate further how HRGP330 interacted with an equimolar amount of 
Figure 3. Stacked plot of 700 MHz 1D 1H-NMR spectra showing the fingerprint region of HRGP330 in the 
presence of varying amounts of ZnCl2. 0.5 mM samples were prepared in 50 mM Tris[D11], 50 mM NaCl with 
10% D2O at pH* 6.2 and 278 K. Aromatic protons from His residues are annotated, but significant overlapping 
of peaks meant they could not be assigned unambiguously in 2D spectra (Figs S3 and S5). A peak corresponding 
to formate (chemical shift standard) is denoted by “f ”.
www.nature.com/scientificreports/
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Zn2+. Since 1H NMR spectroscopy was not able to give detailed structural insights, we explored the utility of 
tandem MS methods to locate Zn2+ ions on HRGP330.
Tandem MS approaches have previously been used to pinpoint preferred interaction sites of metal ions or 
their complexes on proteins. The majority of such studies concern protein modifications with 2nd or 3rd row 
transition metal complexes, especially in the context of anti-cancer metallodrugs based on ruthenium or plat-
inum61–67. Typically, the bonds that such metal ions form with protein side-chains are strong, have significant 
covalent character, and often are kinetically quite inert – hence, the experimental conditions that can be employed 
in a respective MS experiment can be comparatively harsh, both in terms of proton concentration (availability 
of H+ enhances ionisation efficiency in positive ESI-MS) and fragmentation technique. This is in contrast to a 
metal ion such as the 1st row d-block Zn2+, which binds to protein side-chains not only less strongly, but also in 
a much more kinetically-labile fashion, and with bonds usually being very susceptible to proton-induced disso-
ciation. This is the case for HRGP330: Below pH 5, very little zinc is bound to the peptide, even when present 
at a 5-fold excess (Supplementary Fig. S7). Therefore, it is not trivial to maintain zinc binding during ionisation 
and fragmentation in the mass spectrometer. Top-down MS under native conditions, especially in conjunction 
with alternative fragmentation techniques, may offer opportunities to tackle these challenges. Non-covalent pro-
tein assemblies have previously been analysed by MS/MS experiments under (near-)native conditions68–70, and 
examples involving interactions between Zn2+ and proteins/peptides also exist40,71–74. In addition, MS/MS studies 
on the interactions between peptides such as angiotensins and M2+ ions are also available under non-native and 
excess metal conditions39,75,76.
Native mass spectra of apo-HRGP330 and a 1:1 zinc complex of HRGP330, prior to isolation and fragmen-
tation, are shown in Supplementary Fig. S8. Both species were subjected separately to collision-induced dis-
sociation (CID) and electron-transfer dissociation/proton transfer reaction (ETD/PTR) fragmentation. CID 
typically cleaves the peptide bonds, and produces predominantly b and y ions (Biemann notation) whereas ETD 
is a radical-driven fragmentation technique which generates a series of c and z ions following cleavage of N-Cα 
bonds. ETD can be implemented on a range of MS instruments and is, like the FT-ICR-MS (Fourier-Transform 
Ion Cyclotron Resonance Mass Spectrometry) based electron capture dissociation (ECD77, thought to be a 
non-ergodic process78. As a consequence, weak interactions may be preserved during fragmentation. For this 
reason, ECD and ETD are particularly valuable for the identification and localisation of post-translational mod-
ifications79. ETD can be followed by proton transfer reaction (PTR) which decreases the charge states of the 
ETD-fragments produced, thus simplifying the resulting spectra and allowing easier peak assignment.
In both fragmentation approaches and for both apo-HRGP330 and the Zn1-HRGP330 complex, the 5+ 
charge state was selected for fragmentation as this showed the greatest intensity (Supplementary Fig. S8), and also 
because higher charge states are more favourable for fragmentation by ETD. For the metal-free peptide, the 868.0 
m/z ion ([M+5H]5+) was isolated and fragmented using CID and ETD. The annotated product spectra are shown 
in Figs S9 and S10. The Biemann nomenclature was used to annotate the fragments, and fragmentation schemes 
in Fig. 5 summarise the cleavages that occurred in each experiment.
Good sequence coverage was achieved for apo-HRGP330 in both experiments: 82.9% in the ETD fragmenta-
tion compared to a slightly lower value of 74.6% for CID. This is a common observation; CID often gives rise to 
lower sequence coverage than ETD because ETD typically produces a well-defined ion series, whilst CID cleav-
age efficiency is more sequence-dependent79,80. Yet, full sequence coverage cannot be expected for ETD because 
HRGP330 contains 5 Pro residues, and due to the cyclic structure of prolines, cleavage of their N-Cα bond does 
not lead to dissociation of the peptide.
Figure 4. Effect of Zn2+ binding on the ATD of the 5+ charge state of HRGP330. ATD peaks of Zn2+ bound 
species, given in ms. The sample consisted of 10 µM HRGP330 in 10 mM ammonium acetate (pH 7.4) and 
50 μM Zn. The Zn1-HRGP330 peak identified in the sample was too low in intensity to give reliable data. The 
trace for the apo-peptide was acquired on a zinc-free sample. ATD data for all charge states for apo-HRGP330 
are shown in Fig. S6.
www.nature.com/scientificreports/
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In the case of zinc-bound HRGP330, the 880.5 m/z peak ([HRGP330+Zn+3H]5+) was selected for fragmen-
tation. CID of Zn2+-bound HRGP330 produced a larger number of fragment ions than CID of apo-HRGP330, 
suggesting that additional fragments with Zn2+ ions bound were potentially formed (Supplementary Fig. S11). 
Indeed, a number of Zn2+-bound fragments were identified from their characteristic isotopic distributions 
(Fig. S12). Up to approximately 700 m/z, the CID spectra of 868.0 m/z (apo) and 880.5 m/z (Zn1) did not differ 
significantly, indicating that no Zn2+ remained bound to the respective smaller (<b6) or more highly charged and 
smaller (<y112+ or b112+) fragments. Table 1 summarises the Zn2+-bound fragments that were identified and their 
corresponding Zn2+-free fragments (as observed for the apo form).
Figure 5. Fragmentation of the +5 charge states of apo (868.0 m/z) and Zn1-HRGP330 (880.5 m/z) by CID and 
ETD/PTR. Fragmentation schemes are derived from analysis of spectra shown in Supplementary Figs S9–S11 
and S13, using Biotools v3.2 and Sequence Editor v3.2, or manual peak assignments in the case of ETD/PTR 
for 880.5 m/z, where only weak fragment peaks were obtained. The boxes shaded in grey indicate areas where 
cleavage efficiency decreased dramatically upon zinc binding.
Assignment 
of fragment
Experimental 
[M+H]1+
Theoretical 
[M+H]1+
∆mass 
(Da)
Experimental 
[M-H+Zn]1+
Theoretical 
[M-H+Zn]1+
∆mass 
(Da)
y8 1026.68 1026.49 +0.19 1087.54 1087.40 +0.14
y10-NH3 1275.70 1275.57 +0.13 1337.74 1337.50 +0.24
b11 1397.70 1397.64 +0.06 1459.65 1459.55 +0.10
y12 1526.96 1526.71 +0.25 1588.86 1588.62 +0.24
y17 2106.34 2105.97 −0.37 2168.20 2167.89 −0.31
b18 2290.08 2289.93 +0.15 2290.08 2289.93 +0.15
y22 2671.30 2671.22 +0.08 2733.24 2733.14 +0.10
b23 2807.32 2807.28 +0.04 2869.24 2869.19 +0.05
b28 3422.68 3422.52 +0.16 3484.54 3484.43 +0.11
y29 3563.74 3563.60 +0.14 3625.63 3625.51 +0.12
y32 3926.15 3925.80 +0.35 3988.15 3987.71 +0.44
y32-H2O 3908.12 3907.79 +0.33 3970.00 3969.71 +0.29
y33 4125.12 4124.77 +0.35 4125.12 4124.77 +0.35
b33 4082.02 4081.84 +0.18 4144.04 4143.76 +0.28
y34 4176.65 4175.94 +0.71 4238.30 4237.86 +0.44
y34-NH3 4158.60 4158.92 −0.32 4220.65 4220.85 −0.20
Table 1. Summary of Zn2+-bound peptides identified from CID, together with experimental and theoretical 
masses for the respective parent fragment ions.
www.nature.com/scientificreports/
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Many of these are relatively large fragments and do not provide specific information on the location of any pre-
ferred binding site(s). The smallest fragment identified to bind Zn2+ was y8, which suggests that in this fragment, 
the metal ion is interacting with His35, His33, and/or His27. This may indicate that at least three His residues are 
required for sufficiently stable Zn2+ coordination. In addition, fragments from the N-terminal end of the molecule 
were also observed as Zn2+ complexes. Here, the smallest fragment was b11 which indicates that any of the five His 
residues (plus Asp1 and Glu11) in the sequence D1LHPHKHHSHE11 could be coordinating to a Zn2+ ion.
Whilst the CID spectrum of the zinc-bound species (m/z = 880.5) showed a significant amount of fragmenta-
tion which overall was similar to that observed for the apo species, the ETD spectrum (Figs 5 and S13) was domi-
nated by unfragmented Zn-HRGP330 in its +2 and +3 charge states. Fragment peaks were much less intense, not 
well resolved, and also less numerous. This indicates that in the case of this His-rich peptide, complexation with 
Zn2+ had a considerable negative impact on overall fragmentation efficiency. In the light of literature findings 
showing that positively charged, non-redox-active ions support or enhance fragmentation81–86, we suggest that 
this inefficient cleavage for the Zn2+ complex has structural origins (vide infra).
Further manual inspection of the ETD spectra indicated that, similar to the CID spectra, the low m/z range 
of the two ETD spectra showed the same fragment ions. Thus, Zn2+ was, or remained bound, only to larger frag-
ments, some of which are shown in Supplementary Fig. S14. Table 2 summarises the Zn2+-bound peaks identified 
in the ETD spectrum and it is clear that there are fewer than for the CID spectrum, and that most pertain to large 
fragments. The smallest ion identified to have a Zn2+ ion bound was, at low intensity, [z13+Zn]2+ (Fig. S14).
This would suggest that potentially any combination of six histidines (His35, His33, His30, His27, His25 or 
His23) could be involved in binding. There was a significant increase in the intensity of the y7 ion (911.61 m/z) 
in the presence of Zn2+ (Supplementary Fig. S15). This ion is the product of a secondary cleavage reaction of a z 
fragment. Its increase for the Zn1-HRGP330 species suggests that the presence of Zn2+ in the 5+ precursor ion 
affects the way this fragments further. The fragmentation scheme in Fig. 5 indicates that the z8 ion was observed 
only for Zn-HRGP330, and that cleavages between His25, Glu26, His27 occurred only in the absence of Zn. Such 
changes in fragmentation suggest that the Zn2+ ion is bound in the vicinity. Thus the data support the notion that 
this region, which harbours a HxH motif and also includes two carboxylates (with negative charges at least in 
solution), is one favourable location for zinc binding.
The most striking difference between the fragmentation patterns observed for the Zn1 and the apo peptide, 
irrespective of the fragmentation technique, concerned the central region around Gly16: Whilst for the apo pre-
cursor ion, all expected cleavages were observed in both CID and ETD spectra, no cleavages were observed 
between Pro14 and His17 when the Zn-bound species was fragmented by CID. In the ETD spectrum, the overall 
number of cleavages between Glu11 and His20 was reduced from six to two (Fig. 5). Clearly, the presence of Zn2+ 
in the precursor ion has affected the fragmentation efficiency in this region most dramatically. We note that this 
region also contains two HxH motifs.
Notably, a low degree of fragmentation is a commonly observed behaviour for folded proteins subjected to 
ECD or ETD under native ESI-MS conditions36. It is plausible that the lack of fragmentation is due to the middle 
part of Zn1-HRGP330 adopting a more rigid structure that is less susceptible to fragmentation. This stabilisation 
by Zn2+ binding also seems to provide limited protection from CID. This notion is consistent with the conclusions 
from ion mobility MS data which indicated that the HRGP330 structure becomes more compact when Zn2+ 
binding occurs.
Finally, given that fragments from both N-terminal and C-terminal ends of the molecule were observed to 
have a corresponding Zn2+-bound fragment in either CID (e.g. b11 and y8) or ETD (e.g. c20 and z13), it is likely that 
several sites are partially occupied when Zn2+ is present in sub-stoichiometric amounts. In summary, although 
some sites may be more favourable than others, it is clear that there is not a single preferred binding site for Zn2+ 
on HRGP330, but that Zn2+ binding in various locations modulates or decreases fragmentation.
Assignment 
of fragment
Experimental 
[M+H]1+
Theoretical 
[M+H]1+
∆mass 
(Da)
Experimental 
[M-H+Zn]1+
Theoretical 
[M-H+Zn]1+
∆mass 
(Da)
z13* 1648.06 1647.75 +0.31 1711.06 1711.56 −0.50
c20 2479.50 2479.15 +0.35 2542.50 2542.65 −0.15
c26 3187.68 3187.46 +0.22 3250.62 3250.96 −0.34
c27 3324.82 3324.52 +0.30 3388.68 3388.02 +0.66
c28 3439.82 3439.54 +0.28 3502.76 3503.04 −0.28
z28* 3410.76 3410.52 +0.24 3473.76 3474.02 −0.26
z29* 3547.82 3548.58 −0.76 3611.62 3612.08 −0.46
z30* 3676.76 3676.68 +0.08 3739.62 3740.18 −0.56
z31* 3812.76 3812.74 +0.02 3876.82 3876.24 +0.58
c31 3833.76 3833.75 +0.01 3986.82 3897.25 +0.57
z33* 4047.94 4047.85 +0.09 4110.82 4111.35 −0.47
z34* 4160.94 4160.94 0.00 4223.82 4224.44 +0.62
c34 4195.94 4195.92 +0.02 4258.94 4259.42 −0.48
Table 2. Summary of Zn2+-bound peptides identified from ETD/PTR, together with experimental and 
theoretical masses for the respective parent fragment ions. *For the fragments labelled with an asterisk, (z + 2) 
ions were also observed.
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Discussion
This work has investigated the Zn2+ binding properties of a biologically active peptide from the histidine-rich 
region of HRG. Using native ESI-MS, up to six Zn2+ ions were observed to bind to HRGP330. An NMR approach 
was used to investigate structural changes upon Zn2+ binding. The uniform broadening of all His side-chain and 
most backbone resonances upon addition of a single molar equivalent of Zn2+, suggested that there is no single 
preferred binding site in HRGP330, and that the system contains several species in intermediate exchange. This 
broadening and peptide aggregation hampered detailed conclusions regarding the structure of these species. 
TWIM-MS showed that Zn2+ binding increased conformational diversity, as indicated by the observation of 
broader ATDs. Moreover, the average arrival times for HRGP330 with one or more Zn2+ ions bound were shorter 
than for the apo-peptide. These observations indicate that Zn2+ coordination does not stabilise one particular 
structure, even though the conformations of zinc-bound species are more compact.
Top-down MS/MS under native ESI conditions was explored as a tool to study whether preferred locations 
for Zn2+ binding could be discerned. The apo-form of HRGP330 could be fragmented by both CID and ETD 
with high levels of sequence coverage, most likely due to its flexible and extended conformation which allows 
it to fragment readily. When Zn2+ was bound to HRGP330, cleavage efficiency was markedly reduced in both 
cases, indicating that the Zn2+-induced conformational changes and compaction detected by TWIM-MS ren-
dered it less amenable to fragmentation. Nevertheless, Zn2+-bound fragments were identified in both CID and 
ETD data by their mass shift from the corresponding zinc-free fragments and their isotopic distribution. The 
analysis of fragments and that of missing cleavages indicated that the metal ion bound to several different regions 
of the peptide, providing direct evidence for the suggestion that there is not a single clearly preferred binding 
site. This diversity in speciation may at least partially explain the broadness of the ATDs in TWIM-MS, as well 
as the appearance of the 1H NMR data: The different species have different conformations, and it is likely that 
Zn2+ ions can move between sites of similar affinity on an intermediate (NMR) timescale. Taking into account 
the fairly fast ligand exchange rates of Zn2+, this is consistent with the modest Zn2+ affinity reported for mam-
malian HRGs, with reported dissociation constants lying in the low micromolar range30,87,88. It is most probable 
that HRGP330 (and by inference HRG and many other proteins with His-rich regions) remains disordered also 
in the presence of Zn2+. Collectively, these multiple flexible metal-binding sites increase, statistically, the affinity 
of HRGP330 and similar protein regions for Zn2+ ions whilst simultaneously providing a Zn2+-binding module 
with high kinetic lability. This situation is reminiscent of metallothioneins: these predominantly intracellular 
Cys-rich proteins are also structurally disordered in their apo form, and combine high thermodynamic stability 
with high kinetic lability of metal binding – with the important difference of forming well-ordered structures in 
the presence of Zn2+ 89. Zn2+ affinity constants for metallothioneins are about six orders of magnitude larger than 
those of His-rich sequences. It may be suggested that the affinity of the various proteins are matched to the typical 
Zn2+ concentrations they need to deal with or operate at. Basal free Zn2+ concentrations in extracellular media 
are in the low nanomolar range90, and there will be little formation of HRG-Zn2+ complexes. However, free Zn2+ 
concentrations are subject to considerable temporal and spatial fluctuations and can rise to tens or hundreds of 
micromolar. These fluctuations are not random, but highly specific signals that (co-)regulate physiological pro-
cesses91. In the case of HRG and its HRR-containing proteolytic fragment (Fig. 1), there is strong evidence that the 
regulatory zinc signals stem from platelets92. Their activation triggers the secretion of large quantities of Zn2+. In 
this way, the recruitment of platelets to sites of injury such as tumours and wounds, followed by their activation, 
generates a Zn2+-rich microenvironment92. This has implications for angiogenesis15 in malignant tumours93 and 
physiological haemostasis29,30,94,95. In both processes, Zn2+ binding to HRG, or some of its histidine-rich deriv-
atives, increases the affinity to poly-anionic biomolecules, specifically heparin and cell surface-bound heparan 
sulfate. It is evident that the addition of positively charged Zn2+ ions to neutral His residues has the potential to 
greatly enhance binding to negatively charged heparin/heparan sulfate via electrostatic interactions, but previous 
work has shown that the role of Zn2+ goes beyond the provision of positive charge.
The zinc-dependent interaction of the HRR-containing proteolytic fragment and some of its derivatives with 
heparan sulfate on the surface of endothelial cells alters focal adhesion and inhibits their chemotaxis, a crucial 
process in angiogenesis32. Several peptides derived from the HRR have been tested for heparin and heparan 
sulfate binding ability, but only HRG330 and a shorter fragment HRGP335, which lacks five residues from the 
N-terminus and four from the C-terminus, and has an Arg378Glu substitution (Fig. 6), were able to bind heparin 
with similar affinity to full-length HRG and show anti-angiogenic activity. Even shorter peptides retained activity 
in chemotaxis assays34. In contrast, the highly similar HRGP365 (Fig. 6) has much lower heparin-binding ability 
than HRGP330 and is unable to inhibit angiogenesis. It therefore had been postulated that Zn2+ would elicit a 
structural change or stabilise a conformation that favours recognition of heparan sulfate or heparin15,34. Our 
finding that Zn-bound structures are overall more compact than apo-HRGP330 are broadly in line with these 
Figure 6. Comparison of the amino acid sequences of HRGP330 with active (HRGP335) and inactive 
(HRGP365 and HRGP398) peptides derived from the proteolytic fragment of HRG33. All His residues present 
in the active HRGP335 are conserved in the inactive HRGP365, which contains two additional His residues in 
the equivalent region. The His/Cys/Pro-rich peptide HRGP398 was also inactive.
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suggestions, but the increased conformational diversity observed upon Zn binding, and simultaneous occurrence 
of multiple configurational species emphasise the importance of structural dynamics.
Typically, the binding and activity assays mentioned above were carried out in the presence of excess Zn2+ 
(e.g. ca. 5–10-fold) under physiologically relevant conditions33,34,92. Based on our data, it can be expected that at 
least 5 binding sites in HRGP330 would have been saturated. Based on literature findings and our observations, 
it is possible that in the Zn5 species, different Zn ions fulfil different purposes – provision of positive charge on 
the one hand, and aiding in achieving a conformation favourable for interaction with particular heparan sulfate 
sub-structures on the other.
Haemostasis, the first step in wound healing, is dynamically regulated by Zn2+ 29, again with platelets as 
central players. Several lines of evidence indicate that HRG is a central part of this dynamic regulation30,94,95. 
Zinc-mediated HRG-heparin interactions promote blood clotting, as they decrease anti-coagulatory heparin/
anti-thrombin complex formation29. It is evident that such interactions must be transient, in order to enable 
eventual stopping of the clotting process. Although the effects of Zn2+ on haemostasis are much more complex 
and also include anti-coagulatory and fibrinolytic activities29, it can be envisaged that subsequent removal of Zn2+ 
from the vicinity of the clot, for example by binding to highly abundant serum albumin, is facilitated by the high 
kinetic lability of HRG-bound Zn2+.
Finally, it may be added that His-rich peptides and proteins and their interactions with Zn2+ are well suited to 
providing a fairly strong, yet multifunctional3,6 adaptor module. It is thus no surprise that HRG has been named 
the “Swiss army knife of mammalian plasma”13.
Methods
Materials. The HRGP330 peptide was obtained from the Keck Biotechnology Research Facility (Yale 
University, CT, USA). The peptide sequence is DLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPH with 
additional modifications of an acetylated N-terminus and amidated C-terminus. Analytical grade ammonium 
acetate, deuterated Tris, sodium chloride, zinc acetate and zinc chloride were obtained from Sigma-Aldrich 
(Poole, UK).
Purification of HRGP330. Further purification of a crude HRGP330 preparation was achieved 
using reverse-phase high performance liquid chromatography (RP-HPLC) on an Agilent 1100 instrument. 
Approximately 5 mg of crude peptide was solubilised in 4:1 water:acetonitrile containing 0.1% TFA and injected 
onto a Jupiter Proteo 90 Å column (Phenomenex, Macclesfield, UK). The peptides were eluted at 1 mL/min with a 
linear gradient of acetonitrile, and absorbance was monitored at 220 nm. Pooled HPLC fractions were combined 
in a round-bottomed flask and concentrated on a rotary evaporator for 10 minutes. The solution was aliquoted 
and freeze-dried, followed by storage at −20 °C until required. Due to the lack of aromatic amino acids in the pep-
tide sequence, Scopes’ equation was used to estimate the concentration by measuring the absorbance at 205 nm96.
Native ESI-MS. HRGP330 was reconstituted in 10 mM ammonium acetate (pH 7.4) and desalted using 5 
mL polyacrylamide columns (Thermo Fisher Scientific, Hemel Hempstead, UK). Zinc acetate stock solutions 
were prepared in ultrapure water and added to HRGP330 in microlitre aliquots to achieve metal: peptide ratios 
ranging from 1:1 to 5:1. Positive electrospray mass spectra were acquired on a maXisTM UHR-Q-TOF instrument 
(Bruker Daltonics, Coventry, UK) calibrated with sodium formate. A syringe pump injected the sample into the 
mass spectrometer at a rate of 90 µL/hr. Raw data were collected for 2 minutes over a m/z range of 500–1500. 
The following conditions were used for the Q-TOF mass spectrometer: Dry gas = 4.0 L/min; dry gas tempera-
ture = 453 K; funnel RF = 400 Vpp; multiple RF = 400 Vpp; ISCID = 0 eV; collision cell energy = 10 eV; collision 
RF = 1300 Vpp; ion cooler = 650 Vpp; transfer time = 148.4 µs. The data were averaged and deconvoluted using 
Bruker Compass analysis software.
1H-NMR spectroscopy. Samples of HRGP330 (0.5 mM) were prepared in 50 mM [D11]Tris-Cl, 50 mM 
NaCl, 10% D20, at pH* 6.20. Additions of Zn2+ ions were achieved using microlitre aliquots of 50 mM ZnCl2. 
1H-NMR spectra were recorded on an Avance 700 UltrashieldTM spectrometer (Bruker BioSpin) which had an 
operating frequency of 700.13 MHz for 1H. Suppression of the water signal was achieved using excitation sculpt-
ing with gradients97. The 1D spectra were obtained at 278 K using 4k complex data points and 128 scans. In the 
2D [1H, 1H] total correlation (TOCSY) and nuclear Overhauser (NOESY) experiments, spectra were acquired 
with 32 scans over 4k data points in the F2 dimension and 512 increments in F1. The spectral width was 13 ppm 
in both dimensions. A spin lock of 60 ms for the TOCSY and mixing time of 500 ms for the NOESY experiment 
were used. The raw data were apodised using shifted sine-bell functions and Fourier-transformed with 2k × 2k 
data points in F2 and F1. Baseline correction was employed in both dimensions. Spectra were processed using 
TOPSPIN 2.1 (Bruker BioSpin).
Comparison of apo- and Zn-bound HRGP330 using TWIM-MS. Samples of HRGP330 were pre-
pared using the same procedure as described above under “native ESI-MS”. HRGP330 (10 µM) in 10 mM ammo-
nium acetate (pH 7.4) was injected via a nanoflow source into a Synapt HDMS G2 system (Waters Corporation, 
Milford, MA, USA)98. The instrument was operated in the positive mode with a source temperature of 363 K. 
The following instrumental conditions were used: backing pressure 2 mBar, capillary voltage 1.2 kV, cone voltage 
40 V, helium cell gas flow 180 mL/min, IMS cell gas flow 90 mL/min, travelling-wave height 40 V and travelling 
wave velocity 700 m/s. A mass acquisition range of 200–1500 m/z was used. The ion mobility data were calibrated 
with polyalanine which had been analysed under the same conditions. Data were analysed and processed using 
MassLynx v4.1 (Waters).
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MS/MS experiments. MS/MS experiments were carried out using a dual ion funnel AmaZon speed ETD 
instrument (Bruker Daltonics) operating in positive mode. HRGP330 was infused at a rate of 6 μL/min and acqui-
sitions were performed using a scan speed of 8100 m/z per second. The following parameters were used: trap 
drive = 71.8; capillary exit = 140 V; source temperature = 453 K. An isolation width of 4 m/z was used to select the 
ion of interest and CID was performed by applying an amplitude of 1.0 V. Fluoranthene was used as the electron 
transfer dissociation reagent with an ETD reaction time of 100–120 ms, followed by a proton transfer reaction 
(PTR) time of 75 ms. Monoisotopic peaks were assigned using the SNAP™ peak detection algorithm. Spectra 
were analysed using BioTools v3.2 and Sequence Editor (Bruker Daltonics).
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